Adamson T A
Neuropyschiatric Hospital Aro, Abeokuta.
West Afr J Med. 1995 Oct-Dec;14(4):194-7.
Chlorpromazine was administered over a 4-8 week period to 40 schizophrenic patients who had not received previous neuroleptic drug treatment out of a total of 222 schizophrenic patients seen during the study period. Pre-treatment spontaneous eye blink rate was high in the 40 schizophrenics when compared to 34 normal controls, (22 vs 14 blinks/min respectively, t = 17.04, df = 72, p < 0.001). Clinical improvement in the schizophrenic patients correlated with a significant reduction in their pre-treatment versus post-treatment spontaneous eye blink rate (22 vs 9 blinks/min, t = 18.83, df = 78, p < 0.001). The blink rate in the clinically-well schizophrenic patients did not however, reach the level obtained in the normal controls but rather was lowered significantly (9 vs 14 blinks/min, t = 8.11, df = 72, p < 0.001). Blink rate changes in schizophrenic patients on neuroleptic treatment may serve as a quick bedside assessment of clinical improvement and can also be a pointer to those patients who may have sub-clinical drug induced parkinsonism.
在研究期间所见的222例精神分裂症患者中,选取40例未曾接受过抗精神病药物治疗的患者,给予氯丙嗪治疗4至8周。与34名正常对照者相比,40例精神分裂症患者治疗前的自发眨眼率较高(分别为22次/分钟和14次/分钟,t = 17.04,自由度 = 72,p < 0.001)。精神分裂症患者的临床改善与治疗前和治疗后自发眨眼率的显著降低相关(22次/分钟与9次/分钟,t = 18.83,自由度 = 78,p < 0.001)。然而,临床症状改善的精神分裂症患者的眨眼率并未达到正常对照者的水平,而是显著降低(9次/分钟与14次/分钟,t = 8.11,自由度 = 72,p < 0.001)。接受抗精神病药物治疗的精神分裂症患者的眨眼率变化可作为临床改善的快速床边评估指标,也可提示那些可能患有亚临床药物性帕金森综合征的患者。